Anterior capsulotomies may be created safely and efficaciously using a femtosecond laser system (Catalys Precision Laser System, Abbott Medical Optics), according to a study published online in the Journal of Cataract & Refractive Surgery.
Anterior capsulotomies may be created safely and efficaciously using a femtosecond laser system (Catalys Precision Laser System, Abbott Medical Optics), according to a study published online in the Journal of Cataract & Refractive Surgery.
Researchers from Moorfields Eye Hospital, London, conducted a prospective consecutive case series that evaluated 1,000 femtosecond laser–assisted cataract cases performed at the hospital between January 2013 and March 2014. During that time, platform software versions 2.15, 2.15.13, and 2.20 of the femtosecond laser system were used. The researchers evaluated the rate of complete capsulotomies that were performed without adhesions and anterior capsule tears.
The researchers found that in 998 of the 1,000 cases (99.8%), a complete 360-degree capsulotomy was present without adhesions or bridging tags. There were no cases of intraoperative tears of the anterior capsule.
There were 2 cases of incomplete capsulotomy: 1 in which the laser was aborted during the procedure and the procedure was completed manually, and 1 in which a single bridging tag adhesion occurred at capsulotomy removal, and a radial tear was identified after removal of the nucleus. The tear did not extend to the posterior capsule.
To read the abstract of the study, click here.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.